Catalent Experts To Discuss Oral Peptide Delivery And Advanced Modelling To Optimize Formulation At Upcoming Controlled Release Society Conference

SOMERSET, N.J. – July 17, 2018 — Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that its scientific and formulation experts will be attending and contributing to the educational agenda at the upcoming Controlled Release Society (CRS) Annual Meeting and Exposition, to be held at the New York Hilton Midtown Manhattan Hotel, New York, on July 22 – 24, 2018.

A two-day, pre-meeting workshop will provide an update on the progress in oral peptide delivery since the CRS Workshop on this topic in 2014. On Saturday, July 21 at 3:45 p.m., Ronak Savla, Pharm.D., Ph.D., Scientific Affairs Manager, Catalent, will lead a session, presenting “Parallel screening approach for the oral delivery of peptides.”

Dr. Savla will also host a roundtable on Monday, July 23 at 1:30 p.m., entitled “Inflection Point of Drug Formulation: Advanced in silico Applications for Rational Drug Development,” where industry experts, including Jan Neelissen, Ph.D., Scientific Adviser, Catalent, will discuss how harnessing the power of in silico modeling and simulation technologies, along with in vitro studies can result in faster development of drugs, less attrition, reduced costs and, most importantly, better treatments for patients.

Catalent scientists will also be presenting two scientific posters during the event:

  • “Use of a Fiber-optic Low Volume Dissolution Technique to Quantitatively Measure the Delayed Release and Determination of Coating Level of Ibuprofen” and;
  • “Formulation Approaches to Reduce Unpleasant Side Effects of Omega-3 Fish Oil Soft Gelatin Capsules.”

For more information visit the Catalent booth 53, or go to

To arrange a meeting with any of the attending Catalent executives at the event, contact Richard Kerns at NEPR -

Media Contacts:

Chris Halling
+44 (0)7580 041073

Richard Kerns
+44 (0) 161 728 5880

About Catalent 

Catalent is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. With over 80 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs approximately 11,000 people, including over 1,400 scientists, at more than 30 facilities across five continents, and in fiscal 2017 generated over $2 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit

More products. Better treatments. Reliably supplied.™